Status : Published Published On : Oct, 2021 Report Code : VRHC1235 Industry : Healthcare Available Format : Page : 280

Global Digital Biomarkers Market – Analysis and Forecast (2021-2027)

Industry Insight by System Component (Data Collection Tools (Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, and Biosensors) and Data Integration Systems), by Therapeutic Area (Cardiovascular Diseases, Neurodegenerative Disorders, Sleep and Movement Diseases, Psychiatric Disorders, Chronic Pain, Gastrointestinal Diseases, Diabetes, Respiratory Diseases, and Others), by Application (Wellness, Disease Diagnosis, Personalized Medication, and Drug Discovery and Development), by Development Status (Novel Digital Biomarkers, Original Digital Biomarkers, and Approved Digital Biomarkers), by End-User (Pharmaceutical Companies & Labs, Healthcare Providers, and Insurance Payers),and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World)

Industry Overview

The global digital biomarkers market was valued at USD 600.3 million in 2020 and is anticipated to be valued at USD 5,937.4 million by 2027, growing at significant CAGR of 41.25% during the forecast period 2021-2027. A biomarker is an objective measure that captures physiological, pathological or anatomical features of a person in order to understand the state of being and, specifically, an alert system of the body. The rapid growth of digital tools like smartphones and wearables across the world helps in the faster collecting of health information by these devices and also includes information collected by digital biomarkers. The digital biomarkers are of great help for the patient suffering from chronic diseases as these digital biomarkers help to monitor the patient’s condition regularly and provide quality care.  Moreover, it helps the doctor to measure and track symptoms of the patient so as to prevent the progression of irreversible diseases like Parkinson’s and Alzheimer’s. Also, digital biomarkers are used in various applications for clinical trials and clinical care.

The COVID-19 pandemic is adopting digital biomarkers to expedite the screening and diagnosis of COVID-19 patients remotely. For instance, the National Institutes of Health (NIH) has developed physIQ with advancing and validating an algorithm, that can use existing wearable biosensor-derived analytics to discover a novel digital biomarker for COVID-19 associated decompensation.

Market Segmentation

Insight by System Component

Based on system component, the global digital biomarkers are segmented into data collection tools and data integration systems. The data collection tools are further segmented into digital platforms, mobile apps, desktop-based software, wearable, and biosensors. The proliferation of digital tools like wearables and smartphones globally which increase the health information collected by these devices. Moreover, digital biomarkers are used to treat patients suffering from chronic diseases.  Moreover, less cost and enhanced scalability of digital biomarkers in the smartphone apps will help in providing social, behavioral, psychological and environmental data which was inaccessible formerly.

Insight by Therapeutic Area

Based on therapeutic area, the global digital biomarkers are divided into cardiovascular diseases, neurodegenerative disorders, sleep and movement diseases, psychiatric disorders, chronic pain, gastrointestinal diseases, diabetes, respiratory diseases, and others.  Among the segments, cardiovascular disease holds the largest share in 2020 as digital biomarkers provides in-depth insights in the cardiac patient’s response during standardized activity and improve cardiac rehabilitation outcome. Moreover, chronic pain is anticipated to witness the fastest growth during the forecast period 2021-2027 owing to the advancement and adoption of AR and VR solution in detection and treatment of chronic pain.

Insight by Application

Based on application, the global digital biomarkers market is divided into wellness, disease diagnosis, personalized medication, and drug discovery and development. The drug discovery and development is growing at a significant pace owing to the rising adoption of AI and cloud-based services for efficient and cost-effective drug discovery in the pharmaceutical industry.

Insight by Development Status

Based on development status, the global digital biomarkers market is categorized into novel digital biomarkers, original digital biomarkers, and approved digital biomarkers. Among the segments, approved digital biomarkers is anticipated to witness the largest revenue in the market owing to its reliability and are legally authentic as it is FDA approved.

Insight by End-User

Based on end-user, the global digital biomarkers market is divided into pharmaceutical companies & labs, healthcare providers, and insurance payers.  Pharmaceutical companies is anticipated to have the highest share owing to the development of drugs resulted in the generation of novel data from the digital biomarkers diagnostics. This will researchers to understand the progression of the disease and know the performance of the patients towards the drugs. Thus, helping pharmaceutical companies to develop tailored drugs according to patient’s specification, resulting in the growth of the global digital biomarkers market.

Industry Dynamics

Industry Trends

The adoption of high-speed networks like 3G and 4G, development in information technology along with rising demand for solutions that helps in efficiently reducing the healthcare cost and treat chronically ill patients are the trends for the development digital solutions for biomarkers.  

Growth Drivers

Factors driving the growth of the global digital biomarkers can be attributed to the rising adoption of connected digital devices, heath related mobile applications, rising smartphone penetration, rising number of industry players, and emergence of wearable devices. Moreover, significant product launch, favorable government initiatives, FDA approval, failure of drugs for neurodegenerative disorders requires alternatives, increasing cases of health issues such as mental health problems, diabetes, BP, cardiovascular diseases, etc.  will propel the growth of the global digital biomarkers market. The cost of developing a drug is increasing owing to extensive R&D involved as a result biomarker will target the avenues where research needs to be focused, resulting in decreasing the number of processes which in turn will reduce the cost.

Challenges

Factors that challenge the growth of digital biomarkers market assess the data from the biases, validation testing, interoperability and integration, and its cost.

Opportunities

The advent of personalized medicine, huge investment in voice-based digital biomarkers and investment in wearable technology are the opportunities prevalent in the global digital biomarkers market.

Geographic Overview

North America is anticipated to hold the largest market in the digital biomarkers market owing to strong presence of leading industry players, rising investment in R&D, rising product launches, and increasing approval of smart devices in the region.  Asia Pacific is projected to grow at a faster pace owing to the increasing emphasis by government on enhancing healthcare infrastructure, increasing adoption of smart devices, increasing incidences of COVID-19 outbreak, and presence of many patients having chronic diseases in the region.

Competitive Insight

The industry Players are focusing on R&D in the product development and wants to build their brand value. Various other strategies such as mergers and acquisitions, collaborating with research and medical institutions, and expanding their presence in the digital biomarkers market.

FDA cleared two AI-enabled wearable devices, specifically designed to monitor patient's vital signs. KardiaMobile, by AliveCor, is the first device to have received FDA clearance. It detects three of the most common heart arrythmias.

Some of the key players operating in the global digital biomarkers market: AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.

 

 

Frequently Asked Questions

The global digital biomarkers market was valued at USD 600.3 million in 2020 and is anticipated to be valued at USD 5,937.4 million by 2027, growing at significant CAGR of 41.25% during the forecast period 2021-2027
Factors driving the growth of the global digital biomarkers are the increasing adoption of connected digital devices, heath related mobile applications, rising smartphone penetration, favorable government initiatives, rising cases of health issues such as mental health problems, diabetes, BP, cardiovascular diseases, etc. will propel the growth of the global digital biomarkers market.
Asia-Pacific is projected to grow at a faster pace in the global digital biomarkers market during the forecast period 2021-2027.
North America is anticipated to hold the largest market in the digital biomarkers market.
Some of the key players operating in the global digital biomarkers market: AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Place an order

Research Methodology

  •  Desk Research / Pilot Interviews
  •  Build Market Size Model
  •  Research and Analysis
  •  Final Deliverabvle
Digital Biomarkers Market